News | 18 March 2024
AstraZeneca to acquire Amolyt Pharma
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Both organisations enter into a long- term collaboration to expand patient access in India
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
More than 10,000 scientific publications containing EUDRAGIT
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
The drug will target specific genetic mutations prevalent in certain types of cancers
Cureskin aims to disrupt the large and growing skin and hair care industry in India
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
This partnership marks a significant step for the Company towards establishing renewable energy power generation using hybrid open excess through solar and wind sources
New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs
Venus Remedies' manufacturing unit, located in Baddi, Himachal Pradesh, has been recommended for supplying cephalosporin dry powder to UNICEF
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
Zydus Lifesciences receives EIR report from USFDA for API Ahmedabad facility
Women emerge as the cornerstone of this monumental undertaking
The product combines proven efficacy of Doxylamine succinate 20 mg and Pyridoxine hydrochloride 20 mg in an Extended Release formulation
The plan is to set up an ultramodern Solvent Recovery Plant for third party purposes
Subscribe To Our Newsletter & Stay Updated
